Session » Osteoarthritis – Clinical Poster II (0723–0738)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0729

A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects

8:30AM-10:30AM: Abstract Number: 0733

A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain

8:30AM-10:30AM: Abstract Number: 0731

An Open-Label Study to Evaluate the Effect of Intra-articular Triamcinolone Acetonide Extended Release on Patients with Baseline Synovitis and Osteoarthritis of the Knee

8:30AM-10:30AM: Abstract Number: 0736

Decrease in Prevalence of Self-Reported Anxiety or Depression in Persons with Osteoarthritis After Total Knee Arthroplasty: The BEST KNEE Cohort Study

8:30AM-10:30AM: Abstract Number: 0724

Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee

8:30AM-10:30AM: Abstract Number: 0725

Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia

8:30AM-10:30AM: Abstract Number: 0737

Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression

8:30AM-10:30AM: Abstract Number: 0728

Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study

8:30AM-10:30AM: Abstract Number: 0726

Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm

8:30AM-10:30AM: Abstract Number: 0734

Primary Total Knee Arthroplasty for Knee Osteoarthritis Among Younger versus Older Individuals: Cross-sectional Study of Surgical Appropriateness and Surgeon Decision-Making

8:30AM-10:30AM: Abstract Number: 0730

Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study

8:30AM-10:30AM: Abstract Number: 0723

Size of Regression to the Mean in First-Line Interventions for Osteoarthritis: An Illusion of Effectiveness

8:30AM-10:30AM: Abstract Number: 0738

Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis

8:30AM-10:30AM: Abstract Number: 0732

Topical Rofecoxib for OA of the Knee

8:30AM-10:30AM: Abstract Number: 0727

Total Joint Replacements in Three Phase 3 Studies of Tanezumab in Patients with Osteoarthritis

8:30AM-10:30AM: Abstract Number: 0735

Walking Ability 12 Months After Total Knee Arthroplasty for Osteoarthritis – Gap Between Expectations and Reality: The BEST Knee Cohort Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].